OncoMatch/Clinical Trials/NCT04485013
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Is NCT04485013 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for cancer.
Treatment: TTX-080 · TTX-080 · pembrolizumab · cetuximab · FOLFIRI · cetuximab · TTX-080 — TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent
Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Arizona Oncology Associates · Tucson, Arizona
- University of Southern California · Los Angeles, California
- Hoag Memorial Hospital · Newport Beach, California
- Rocky Mountain Cancer Centers · Denver, Colorado
- Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify